Quent Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$203 Hold
166
– – ﹤0.01% 1634
2026
Q2
$1.62K Sell
166
-69
-29% -$599 ﹤0.01% 1500
2026
Q1
$1.31K Hold
235
– – ﹤0.01% 1423
2025
Q4
$1.73K Buy
235
+4
+2% +$24 ﹤0.01% 1405
2025
Q3
$1.51K Buy
+231
New +$1.24K ﹤0.01% 1288
2025
Q2
– Sell
-231
Closed -$864 – 804
2025
Q1
$864 Sell
231
-2
-0.9% -$17 ﹤0.01% 1228
2024
Q4
$2.36K Hold
233
– – ﹤0.01% 1149
2024
Q3
$2.9K Hold
233
– – ﹤0.01% 1189
2024
Q2
$3.03K Buy
+233
New +$3.86K ﹤0.01% 1166
2023
Q2
– Sell
-26
Closed -$1.5K – 1339
2023
Q1
$1.5K Hold
26
– – ﹤0.01% 1200
2022
Q4
$1.31K Buy
26
+24
+1,200% +$1.66K ﹤0.01% 1198
2022
Q3
$0 Hold
2
– – ﹤0.01% 1246
2022
Q2
$0 Hold
2
– – ﹤0.01% 1246
2022
Q1
$0 Buy
+2
New +$249 ﹤0.01% 1291

Other funds holding KPTI

Quent Capital's KPTI Position: Q3 2026 in Review

Quent Capital held its Karyopharm Therapeutics (KPTI) position steady in Q3 2026 at 166 shares worth $203. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

Quent Capital first reported a position in KPTI in Q1 2022 and has held it in 14 quarters since. The position peaked at $3.03K in Q2 2024. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Quent Capital held 166 shares of Karyopharm Therapeutics worth $203 as of Q3 2026.
  • Quent Capital left its Karyopharm Therapeutics share count unchanged in Q3 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q3 2026, its #1634 holding.
  • Quent Capital first reported a position in Karyopharm Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Quent Capital's Karyopharm Therapeutics position peaked at $3.03K in Q2 2024.
  • 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Quent Capital's 13F filing for Q3 2026, filed 9 Nov 2026.